19.08.2016, 18:03
Adhesion Barrier Market by Product, Product Form , Application
OREANDA-NEWS. Adhesion Barrier Market by Product (Hyaluronic Acid, Fibrin, Regenerated Cellulose, Collagen & Protein), Product Form (Film, Gel, Liquid), Application (General, Orthopedic, Reconstructive, Neurological, & Gynecological Surgeries) - Global Forecast to 2021..., Market Research Report: MarketsandMarkets.
The global adhesion barrier market is expected to reach USD 1,216.8 Million by 2021 from USD 812.5 Million in 2016, at a CAGR of 8.4% during the forecast period of 2016 to 2021. Rising geriatric population, increasing number of surgeries, and growth in the number of sports-related and hand and wrist injuries are the major factors driving the adhesion barrier market. However, limited technological developments as a result of stringent regulations are expected to restrain the growth of this market to some extent during the forecast period.
In this report, the adhesion barrier market is segmented on the basis of product type, product form, application, and geography. Based on products, the market is segmented into natural adhesion barriers and synthetic adhesion barriers. The synthetic adhesion barriers segment is further classified into hyaluronic acid, regenerated cellulose, polyethylene glycol (PEG), and other synthetic adhesion barriers. On the other hand, the natural adhesion barriers segment includes collagen and proteins and fibrin-based adhesion barriers. On the basis of product form, the adhesion barriers market is segmented into film formulations, gel formulations, and liquid formulations. Based on applications, the market is segmented into gynecological surgeries, general/abdominal surgeries, cardiovascular surgeries, neurological surgeries, orthopedic surgeries, thoracic surgeries, urological surgeries, reconstructive surgeries, and other surgeries.
The synthetic adhesion barriers segment accounted for the largest share of the adhesion barrier market in 2015. This is majorly attributed to the widespread use of products such as hyaluronic acid and regenerated cellulose in surgeries.
The major regional segments covered in Adhesion Barrier market are North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa; all these regional segments are further analyzed at a country level. This research report also discusses the key market drivers, restraints, challenges, and opportunities in the global adhesion barrier market and its submarkets.
In 2015, North America commanded the largest share of the adhesion barrier market, followed by Europe, Asia-Pacific, Latin America, and the Middle East and Africa. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period, followed by Latin America. Countries such as India, China, and Brazil are expected to offer significant growth opportunities for players operating in this market during the forecast period.
The major players operating in the adhesion barrier market include Johnson & Johnson (U.S.), Sanofi Group (France), Atrium Medical Corporation (U.S.), Baxter International Inc. (U.S.), Medtronic Plc. (U.S.), C. R. Bard, Inc. (U.S.), Integra Lifesciences Corporation (U.S.), Anika Therapeutics Inc. (U.S.), FzioMed, Inc. (U.S.), and MAST Biosurgery AG (Switzerland).
The global adhesion barrier market is expected to reach USD 1,216.8 Million by 2021 from USD 812.5 Million in 2016, at a CAGR of 8.4% during the forecast period of 2016 to 2021. Rising geriatric population, increasing number of surgeries, and growth in the number of sports-related and hand and wrist injuries are the major factors driving the adhesion barrier market. However, limited technological developments as a result of stringent regulations are expected to restrain the growth of this market to some extent during the forecast period.
In this report, the adhesion barrier market is segmented on the basis of product type, product form, application, and geography. Based on products, the market is segmented into natural adhesion barriers and synthetic adhesion barriers. The synthetic adhesion barriers segment is further classified into hyaluronic acid, regenerated cellulose, polyethylene glycol (PEG), and other synthetic adhesion barriers. On the other hand, the natural adhesion barriers segment includes collagen and proteins and fibrin-based adhesion barriers. On the basis of product form, the adhesion barriers market is segmented into film formulations, gel formulations, and liquid formulations. Based on applications, the market is segmented into gynecological surgeries, general/abdominal surgeries, cardiovascular surgeries, neurological surgeries, orthopedic surgeries, thoracic surgeries, urological surgeries, reconstructive surgeries, and other surgeries.
The synthetic adhesion barriers segment accounted for the largest share of the adhesion barrier market in 2015. This is majorly attributed to the widespread use of products such as hyaluronic acid and regenerated cellulose in surgeries.
The major regional segments covered in Adhesion Barrier market are North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa; all these regional segments are further analyzed at a country level. This research report also discusses the key market drivers, restraints, challenges, and opportunities in the global adhesion barrier market and its submarkets.
In 2015, North America commanded the largest share of the adhesion barrier market, followed by Europe, Asia-Pacific, Latin America, and the Middle East and Africa. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period, followed by Latin America. Countries such as India, China, and Brazil are expected to offer significant growth opportunities for players operating in this market during the forecast period.
The major players operating in the adhesion barrier market include Johnson & Johnson (U.S.), Sanofi Group (France), Atrium Medical Corporation (U.S.), Baxter International Inc. (U.S.), Medtronic Plc. (U.S.), C. R. Bard, Inc. (U.S.), Integra Lifesciences Corporation (U.S.), Anika Therapeutics Inc. (U.S.), FzioMed, Inc. (U.S.), and MAST Biosurgery AG (Switzerland).
Комментарии